FDA advisors have voted 9-0 in favor of approving Moderna's seasonal mRNA flu vaccine, dubbed mRNA-1010 or mFlusiva.
The vaccine was found to be around 27 percent more effective against seasonal flu than a standard flu shot in a Phase 3 trial involving over 40,000 adults age 50 and older.
A smaller Phase 3 trial showed the shot produces stronger immune responses than a high-dose flu vaccine in people age 65 years and older, with a generally good safety profile.
